The percentage of reduced coenzyme Q 10 (CoQ 10 H 2 ) in total coenzyme Q 10 (TQ 10 ) is decreased in plasma of patients with prematurity, hyperlipidemia, and liver disease. CoQ 10 H 2 is, however, easily oxidized and difficult to measure, and therefore reliable quantification of plasma CoQ 10 H 2 is of clinical importance. Methods: Venous blood was collected into evacuated tubes containing heparin, which were immediately placed on ice and promptly centrifuged at 4°C. The plasma was harvested and stored in screw-top polypropylene tubes at ؊80°C until analysis. After extraction with 1-propanol and centrifugation, the supernatant was injected directly into an HPLC system with coulometric detection. 
Coenzyme Q 10 is an essential cofactor in the mitochondrial respiratory chain responsible for oxidative phosphorylation (1 ) . Furthermore, coenzyme Q 10 has a primary function as an antioxidant and is carried mainly by lipoproteins in the circulation (2 ) . Approximately 60% of coenzyme Q 10 is associated with LDL, 25% with HDL, and 15% with other lipoproteins (2 ) . When LDL is subjected to oxidative stress in vivo (3 ), the reduced form of CoQ 10 (CoQ 10 H 2 ) 3 functions as an antioxidant. It has been postulated that CoQ 10 H 2 prevents lipid peroxidation in plasma lipoproteins and biological membranes (4 ) . The antioxidative activity of CoQ 10 H 2 depends not only on its concentration, but also on its redox status. Recent reports (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) have suggested that the percentage of CoQ 10 H 2 in total CoQ 10 (CoQ 10 H 2 :TQ 10 ) may be lower in patients with certain conditions, including Parkinson disease (5 ), prematurity (6 ) , hemodialysis (7 ), chronic active hepatitis (8 ) , liver cirrhosis (8 ) , hepatocellular carcinoma (8 ) , hyperlipidemia (9, 10 ) , heart disease (11, 12 ) , ␤-thalassemia (13 ) , and DNA damage (14 ) . Therefore, CoQ 10 H 2 may be a useful marker of oxidative stress, and the measurement and function of CoQ 10 H 2 are of considerable interest.
Several investigators have reported analytical techniques for measurement of CoQ 10 H 2 (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . In these publications, electrochemical (EC) detection was preferred for measurement of CoQ 10 H 2 because of its high sensitivity. The EC reactions were measured at electrodes, which detected the current produced by the reduction of oxidized CoQ 10 (CoQ 10 ) or by the oxidation of CoQ 10 H 2 ( Fig. 1 ).
Investigation of CoQ 10 H 2 in clinical studies has been hampered by instability during sample handling, storage, and processing (15) (16) (17) (18) (19) (20) (21) . According to several investigators (22) (23) (24) (25) , the concentration of CoQ 10 H 2 decreases rapidly within 1 h after phlebotomy. At room temperature, it is oxidized at a rate of ϳ3 nmol/L per min in the hexane extract of human plasma (23 ) . Sample preparation may have a profound effect on the redox status of CoQ 10 , and the utmost care is required to ensure reliable quantification of CoQ 10 H 2 . Recently, investigators recommended that plasma samples be individually thawed, extracted, and analyzed immediately as a continuous process to minimize CoQ 10 H 2 oxidation (22) (23) (24) . This is very impractical for analyzing even small numbers of biological specimens. In earlier studies, biological fluid samples were converted into either CoQ 10 by use of an oxidizing reagent such as ferric chloride, or into CoQ 10 H 2 by a reducing agent such as sodium tetrahydroborate (NaBH 4 ) or sodium dithionite (Na 2 S 2 O 4 ; Table 1 ). However, these methods are also inefficient, are susceptible to preanalytical degradation, and have increased potential for analytical error because of the lability of CoQ 10 H 2 .
We therefore developed a simple and rapid HPLC procedure with coulometric detection for simultaneous determination of CoQ 10 and CoQ 10 H 2 in human plasma.
Materials and Methods materials
CoQ 10 and coenzyme Q 9 (CoQ 9 ) were obtained from Sigma. Methanol, ethanol, 1-propanol, 2-propanol, hexane, sodium acetate, and glacial acetic acid were obtained from Fisher Scientific. All chemicals were HPLC grade and were used without further purification. Dade ® immunoassay comprehensive tri-level controls were from Dade International.
apparatus
The HPLC-EC system configuration is depicted in Fig. 2 . The system consists of an Model 582 Solvent Delivery Module (ESA) equipped with a double plunger reciprocating pump, an AS3000 variable-loop autosampler (Thermo Separation Products), an analytical column, an ESA CouloChem II Model 5200A EC detector, and a Dell Pentium II 350 Mz computer/controller with ChromQuest software (Thermo Separation Products). The system consisted of two cells (pre-and postcolumn) and an analytical cell (Fig. 2) . One carbon filter was placed before the precolumn cell and another between the analytical column and the postcolumn cell. Both pre-and postcolumn cells (E1 and E2) were coulometric electrodes (ESA Model 5020). The postcolumn cells were configured in series as described by Edlund (17 ) . The analytical cell (ESA Model 5010) consisted of a series of two coulometric electrodes and was connected in series to the postcolumn cell; the first electrode (E3) was for reduction of CoQ 10 , and the second electrode (E4) was for detection of CoQ 10 H 2 .
The analytical column was a reversed-phase Microsorb-MV column (4.6 mm ϫ 15 cm; 5 m bead size; Rainin). A reversed-phase C 18 guard column (4.6 ϫ 10 mm; 5 m bead size) was used to protect the analytical column. The AS3000 injector was set at a needle height of 1.5 mm, and the injection volume was set at 20 L for each sample. The cooling temperature of the autosampler was set at 0°C. The mobile phase for the isocratic elution of CoQ 10 was prepared as follows: sodium acetate trihydrate (6.8 g), 15 mL of glacial acetic acid, and 15 mL of 2-propanol were added to 695 mL of methanol and 275 mL of hexane. The mobile phase was filtered through a 0.2 m (47 mm diameter) nylon or analogous filter. The pH of the mobile phase was ϳ6, and the flow rate was 1 mL/min.
preparation of calibrators
All sample preparation work was carried out under a dim light to avoid photochemical decomposition of CoQ 10 and CoQ 9 . To prepare a 5 mg/L working solution of CoQ 10 , we dissolved 10 mg of CoQ 10 in 10 mL of hexane and diluted this solution to 100 mL with 1-propanol. The solution was thoroughly vortex-mixed until complete dissolution. A working solution was then prepared by dilution with 1-propanol to 5 mg/L. The concentration of the working solution was then calculated by reading the absorbance on a spectrophotometer (275 nm wavelength; 1-cm quartz cuvette), using a molar absorptivity (⑀) of 14 200. A series of calibration solutions was then prepared with the appropriate volume of 1-propanol to final CoQ 10 concentrations of 10, 100, 500, 1000, 2000, and 4000 g/L. The low control was prepared by diluting pooled plasma containing 0.45 mg/L CoQ 10 with distilled water to a final concentration of 75 g/L. The middle and high controls were prepared by adding working solutions containing 1.2 and 3.0 mg/L CoQ 10 to pooled plasma samples to final concentrations of 1.65 and 3.45 mg/L, respectively. The calibrators and controls were stored in 1.8-mL polypropylene tubes (Sarstedt) without addition of argon or nitrogen at Ϫ80°C and used throughout the study. CoQ 9 was chosen as the internal standard. To prepare a CoQ 9 solution, we dissolved 2 mg of CoQ 9 in 100 mL of 1-propanol. The CoQ 9 solution was thoroughly vortexmixed until complete dissolution. A working solution of CoQ 9 was then prepared by dilution with 1-propanol to 2 mg/L. All solutions were stored in 1.8-mL polypropylene tubes at Ϫ80°C and used throughout the study.
preparation of plasma samples
Venous blood was collected into a Vacutainer ® Tube (Becton Dickinson) containing heparin as anticoagulant and mixed by gentle inversion 5-6 times. The Vacutainer Tube was not opened to ambient air and was placed in ice or kept refrigerated before processing. Blood samples were processed within 4 h of collection and centrifuged at 2000g for 10 min at 4°C. Plasma was collected, placed in a capped polypropylene tube, and immediately stored without addition of argon or nitrogen at or below Ϫ80°C until analysis.
liquid-liquid extraction
Under our experimental conditions, we optimized the extracting procedure of Edlund (17 ) and compared the efficiency of different mixtures of organic solvents for liquid-liquid extraction of CoQ 10 and CoQ 9 from human plasma. Quantitative recoveries (ϳ100%) of these compounds were obtained with two solvents: 1-propanol and a mixture of ethanol-hexane (2:5 by volume). The 1-propanol extraction procedure was used for subsequent studies.
coulometric detection
The hydrodynamic voltammograms were obtained by repeated injections into the HPLC system of a mixture of CoQ 9 (1 mg/L) and CoQ 10 (4 mg/L) in water-1-propanol (1:9 by volume). The detector potential was increased by 0.05 V in each subsequent run. Anodic currents for CoQ 10 H 2 and cathodic currents for CoQ 10 reached maximum response at applied voltages of ϩ0.35 V and Ϫ0.65 V, respectively. On the basis of the assessed hydrodynamic voltammogram, the E2 cell potential was always set at ϩ0.7 V to oxidize any electrochemically active eluates. The E3 and E4 cell potentials were set at Ϫ0.65 V and ϩ0.45 V, respectively. When the E1 cell potential was set to Ϫ0.7 V for the precolumn reduction mode, all CoQ 10 was reduced to CoQ 10 H 2 before column separation. Total CoQ 10 H 2 was then measured, and a calibration curve of This system can be operated in three different modes, as described in the text.
CoQ 10 H 2 was established. For the precolumn oxidation mode, the E1 cell potential was set at ϩ0.7 V. All CoQ 10 H 2 was oxidized to CoQ 10 , and TQ 10 was measured. A calibration curve of CoQ 10 was thus obtained. For simultaneous determination of CoQ 10 H 2 and CoQ 10 , the E1 cell was turned off. Because no current flowed into the cell, all compounds remained at their original state.
assessment of possible interfering substances
To explore possible sources of interference, we processed several lyophilized products from human blood, highly purified chemicals, and biochemicals (included in the Dade high control) according to the developed method. Briefly, Dade high control, which contains 45 drugs and endogenous substances, was supplemented with 20 commonly prescribed drugs at concentrations exceeding clinically relevant values (Table 2) ; 100-L aliquots of the supplemented control were then placed in 1.8-mL capped polypropylene tubes, processed, and analyzed.
To assess the possible interference of endogenous CoQ 9 or other substances in patient plasma samples, blood samples were collected from 25 patients (ages 1-18 years) in the neurology clinic at the Children's Hospital Medical Center, Cincinnati, OH. These patients were diagnosed with a variety of neurological disorders. An additional 25 specimens were obtained from apparently healthy individuals (ages 0.2-65 years). Informed consent was obtained from all adults and from the parents (or guardians) of all minors.
sample analysis
We simultaneously processed samples in batches of 20, which is the capacity of our centrifugation instrument. Each frozen sample was thawed at room temperature, and then a 100-L aliquot of the sample was placed in a 1.8-mL capped polypropylene tube containing 50 L of internal standard solution. All tubes were kept in an ice Results efficiency of reduction cell 
chromatographic analysis
As seen in Fig. 3 , CoQ 10 and CoQ 10 H 2 could be measured in the same HPLC run. CoQ 9 and CoQ 10 eluted at ϳ5.5 and ϳ6.9 min, respectively (Fig. 3A) . Two peaks were observed for the reduced form (CoQ 9 H 2 ) of CoQ 9 (internal standard) and CoQ 10 H 2 at ϳ3.6 and ϳ4.1 min, respectively (Fig. 3B) . 
extraction efficiency
Under our experimental conditions, quantitative recoveries of CoQ 10 and CoQ 9 for the current method using 1-propanol were compared with previously published extraction methods (Table 1) . With the 1-propanol method, the mean recoveries were 99% Ϯ 3% for CoQ 10 and 100% Ϯ 2% for CoQ 9 (n ϭ 6). Comparison with other extraction solvents (n ϭ 6 replicates each) produced the following mean recoveries: 2-propanol, 89% Ϯ 5%; ethanol, 88% Ϯ 4%; n-butanol, 85% Ϯ 5%; acetone, 71% Ϯ 8%; methanol-hexane (0. which were kept on ice or in refrigerated at 4°C, were processed identically at hourly intervals up to 8 h after collection. Plasma from each blood specimen was separated and frozen at Ϫ80°C until analysis. The results showed that CoQ 10 H 2 in whole blood stored at 4°C was stable for at least 8 h with a CV Ͻ5%. The mean (SD) ratio of CoQ 10 H 2 :TQ 10 in 25 heparinized whole blood specimens was 95.3% (Ϯ 1.8%) 8 h after blood collection (4°C).
On the basis of these findings, we recommend that blood for CoQ 10 H 2 analysis be refrigerated to ensure sample stability for up to 8 h after collection.
precision and accuracy
The analytical recoveries of CoQ 10 in human plasma controls are shown in Table 3 . The inter-and intraday assay CVs were Ͻ5% over four concentrations of CoQ 10 . Because CoQ 10 H 2 is oxidized rapidly, no control tests for CoQ 10 H 2 were performed. To verify the reproducibility of the CoQ 10 H 2 analysis, human plasma samples from 10 healthy individuals were examined (5 replicates each; Table 4 ). The reproducibility of the analysis is presented in Table 4 . The CVs for the ratio of CoQ 10 H 2 :TQ 10 were Յ1.0%, which shows the excellent reproducibility of analysis.
interference studies
Testing of the supplemented Dade control indicated that a few unidentified electroactive compounds and substances (Table 2) eluted from the column within the first 3.5 min (data not shown). These compounds and substances may have been more hydrophilic than CoQ 10 H 2 because an organic solvent-based mobile phase was used. Only one unknown compound eluted at ϳ6.9 min, which corresponded exactly with the CoQ 10 elution time. Because the Dade control is plasma-based, this peak most likely was residual CoQ 10 in this control. None of the lyophilized products of human blood, highly purified chemicals, biochemicals, and medications added to the Dade High Control produced interference in the analysis. To assess the possible interference of endogenous CoQ 9 with that added as internal standard, 50 plasma samples, including 25 from apparently healthy individuals and 25 from patients, were extracted without adding the internal standard, CoQ 9 . Only one plasma sample, from a patient with a rare glycogen storage disease (type I), was found to have ϳ25 g/L CoQ 9 , which corresponded to ϳ2.5% of the internal standard concentration. Measurable CoQ 9 was not detected in the plasma samples from the remaining 25 healthy individuals or 24 patients. On the basis of these findings, we conclude that interference from endogenous CoQ 9 is very unlikely to cause significant analytical error with our method, and thus is a very suitable internal standard (Fig. 5) .
preliminary reference interval results
To provide preliminary data for establishing the reference interval for the ratio of CoQ 10 H 2 :TQ 10 , plasma specimens were collected from 25 apparently healthy individuals. The CoQ 10 H 2 :TQ 10 ratio was 96.3% Ϯ 2.0% (mean Ϯ SD). The mean plasma concentrations of CoQ 10 H 2 and TQ 10 were 803 (Ϯ 264) and 835 (Ϯ 276) g/L, respectively.
Discussion
Various HPLC-EC methods have been described in the past that attempted to measure CoQ 10 and CoQ 10 H 2 (Table 1) . Because CoQ 10 is somewhat insensitive to EC detection, in-line postcolumn reduction of CoQ 10 to CoQ 10 H 2 by a coulometric method (21, 22, 24 ) or a reduction column (23 ) has been reported recently, which allows for the sensitive detection of CoQ 10 by an EC electrode. Historically, these methods used chemical reagents to obtain CoQ 10 H 2 by reducing the commercially available CoQ 10 . This process typically involves the addition of an excess amount of the reducing reagent to convert CoQ 10 into CoQ 10 H 2 and to maintain the reduced form. Additional care is also required to avoid oxidation by ambient oxygen, usually by storage under argon or nitrogen. Table 1) . Postcolumn EC detectors in the reduction-reduction-oxidation mode, as described by Grossi et al. (19 ) , were used. According to their procedure, 5 or 10 L of sample was extracted with ethanol, ␤-hydroxytoluene, and hexane. After centrifugation, the hexane phase was evaporated to dryness under a stream of argon and redissolved in a mixture of ethanol and methanol. Poor recoveries of 54% Ϯ 37% and 76% Ϯ 36% were reported for CoQ 10 H 2 and CoQ 10 , respectively, without internal standardization by CoQ 9 H 2 and CoQ 9 . To correct this problem, the authors added internal standardization with CoQ 9 H 2 and CoQ 9 . This improved the accuracy and precision, i.e., recoveries were 105% Ϯ 21% and 97% Ϯ 11%, respectively, for CoQ 10 H 2 and CoQ 10 . However, the imprecision of the CoQ 10 H 2 analysis was excessive. The instability of hexane-extracted CoQ 10 H 2 after drying has been reported by other investigators (23 ) and may contribute to this problem. Again, it should be noted that this procedure is relatively tedious and complex. Lagendijk et al. (22 ) also reported a rapid HPLC-EC procedure for the determination of CoQ 10 H 2 and CoQ 10 in 1-propanol extracts (Table 1) . They used the postcolumn EC electrodes in the oxidation-reduction-oxidation mode as described by Edlund (17 ) . Their extraction and analysis procedures without internal standardization were also used to obtain the ratio between CoQ 10 H 2 and CoQ 10 . To prevent a coulometric overload with an 80-L injection of sample, a sophisticated switching valve was used to ensure that only the compounds of interest were channeled through the coulometric cells. Although they used a 1-propanol extraction similar to the one used in the current method, their sample and solvent volumes (300 L and 1 mL, respectively) were much greater than the current method (100 and 900 L, respectively), and their Table 4 . Reproducibility of the analysis of coenzyme Q 10 in human plasma. 
injection volume was fourfold increased (80 L vs 20 L).
In addition, the current method uses in-line precolumn reduction, an autosampler, and cooling of the samples to 0°C. Although the method used by Lagendijk et al. 10 . In addition, CoQ 10 H 2 and TQ 10 determinations must be performed before and after each sample is mixed with reducing agent before HPLC analysis. Because the reducing reagent is very unstable, a fresh and adequate amount of reducing reagent must be prepared every three samples. Previous experience by the current investigators found that excess reducing agent may overload the EC electrode and shorten the life-span of the detector cells (unpublished data). Additionally, the method of Wang et al. (25 ) may be prone to analytical variation because they do not use an internal standard. According to the authors, their method is also limited to the analysis of a maximum of one sample per hour and requires continuous effort by a technician. Although the current procedure requires 100 L of plasma, the sample size could be further reduced to 25 or 50 L depending on the detection of trace amounts of CoQ 10 . Because CoQ 10 H 2 and CoQ 10 are measured simultaneously, the total analysis time is substantially shorter than those for other methods. The method described herein makes it possible to analyze up to 40 samples within an 8-h period. Although other, longer methods have included additional analytes (16 -18, 20, 21, 23 ) , the current method has been optimized to measure CoQ 10 H 2 and CoQ 10 as rapidly, simply, accurately, and precisely as possible. Tables 3 and 4 summarize the excellent reproducibility of the analysis. The individual CVs for CoQ 10 H 2 , TQ 10 , and the CoQ 10 H 2 :TQ 10 ratio were Յ3.8%, Յ3.7%, and Յ1.0%, respectively ( Table 4 ). The current method uses single extraction with 1-propanol as solvent to disrupt lipoproteins and efficiently solubilize CoQ 10 H 2 and CoQ 10 . This eliminates the necessity of the repeated extraction procedures that frequently were required by earlier procedures in which mixtures of either methanol or ethanol and hexane were used. In contrast to earlier methods, no evaporation step and no additional cleanup of the 1-propanol extract are needed. Although Ͼ1000 samples have been injected into the current system over the previous 6 months, the in-line filters have been replaced only once. The current system also avoids the need for complex system configurations, such as coupled columns with column-switching valves and postcolumn two-way valves.
Some controversy exists concerning the use of CoQ 9 as an internal standard for CoQ 10 H 2 analysis. Evidence of endogenous CoQ 9 in some individuals was cited by some investigators (26 ), but not others (27 ) . Our current results and considerable experience indicate that CoQ 9 is rarely found in measurable quantities in human plasma and thus is a suitable internal standard for this procedure.
The ranges for the percentage of CoQ 10 H 2 in TQ 10 from previous reports are quite variable ( Table 1) . The percentages of CoQ 10 H 2 in TQ 10 reported recently, i.e., ϳ95% (21 ), ϳ94% (22 ) , ϳ96% (23 ) , and ϳ93% (25 ) , agree well with the results of the current study (ϳ96%). Other methods may accurately measure CoQ 10 H 2 ; however, they generally are more labor-intensive and more prone to error than the current method. Accurate determination of CoQ 10 H 2 makes it a possible marker for assessing the presence of oxidative stress in many pathologic states. Although significant differences in the plasma CoQ 10 H 2 :TQ 10 ratio between controls and patients with atherosclerosis, coronary artery disease, and Alzheimer disease have not been observed by some investigators (10, 28 ) to one report (7 ), a single hemodialysis session causes a 30% decrease in mean plasma CoQ 10 H 2 concentrations. Plasma CoQ 10 H 2 was also found to be significantly lower in hyperlipidemic patients and in patients with liver disease (10 ) . In 64 patients with chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma, significantly increased CoQ 10 and decreased CoQ 10 H 2 were observed (8 ). Palomäki et al. (12 ) observed that lovastatin treatment diminishes the CoQ 10 H 2 concentration in the LDL of hypercholesterolemic patients with coronary heart disease. There are also concerns that patients could experience deleterious effects as a result of long-term therapy with hydroxymethylglutaryl-CoA reductase inhibitors or "statin" therapy. Monitoring of the effects of statin therapy on CoQ 10 H 2 may be useful for diagnosing CoQ 10 H 2 deficiency in many patient populations. These are but a few of a growing numbers of studies that suggest that CoQ 10 H 2 deficiency may be related to pathophysiologic mechanisms.
Recent studies have reported new findings related to CoQ 10 H 2 that may lead to a better understanding of the cellular function of CoQ 10 H 2 . One study in patients with ␤-thalassemia showed that severely depleted CoQ 10 H 2 concentrations (Ϫ62.5%) are associated with increased plasma concentrations of lipoperoxidation byproducts and urinary concentrations of catecholamine metabolites and azelaic acid (13 ) . These changes may indicate both neurological and lipoperoxidation stress (13 ) . Gotz et al. (5 ) also reported that platelet CoQ 10 H 2 :CoQ 10 ratios were significantly decreased in patients with Parkinson disease. An altered redox state of platelet coenzyme Q 10 may reflect a change in membrane electron transport and the effectiveness of defense against toxic reactive oxygen species, such as hydrogen peroxide and superoxide (5 ) . Another recent study suggested that CoQ 10 enrichment may decrease oxidative DNA damage in human lymphocytes (14 ) . Additional studies are needed to understand the function and protective role of CoQ 10 H 2 in these and other diseases.
In conclusion, we developed a simple, rapid, and isocratic HPLC method for the determination of CoQ 10 H 2 and CoQ 10 in human plasma. An extraction process using 1-propanol as solvent allows rapid and simple sample extraction and minimizes oxidation of CoQ 10 H 2 during sample processing. An in-line precolumn reduction cell is used to convert CoQ 10 into CoQ 10 H 2 . The EC reduction yields 99% CoQ 10 H 2 and avoids the artifactual oxidation that frequently occurs with CoQ 10 H 2 produced through the chemical reduction process. This optimized method provides excellent sensitivity, precision, and accuracy for relatively high-throughput assessment of CoQ 10 H 2 and CoQ 10 in human plasma. This method is suitable for research and can be easily adapted for clinical testing purposes. Studies are in progress to establish reference intervals and to evaluate the clinical significance of plasma and cerebrospinal fluid concentrations of CoQ 10 H 2 in several patient populations.
